Jilin Aodong Pharmaceutical Group Co Ltd banner

Jilin Aodong Pharmaceutical Group Co Ltd
SZSE:000623

Watchlist Manager
Jilin Aodong Pharmaceutical Group Co Ltd Logo
Jilin Aodong Pharmaceutical Group Co Ltd
SZSE:000623
Watchlist
Price: 18.83 CNY -0.16% Market Closed
Market Cap: ¥22.5B

Relative Value

The Relative Value of one Jilin Aodong Pharmaceutical Group Co Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 18.83 CNY, Jilin Aodong Pharmaceutical Group Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Jilin Aodong Pharmaceutical Group Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Jilin Aodong Pharmaceutical Group Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Jilin Aodong Pharmaceutical Group Co Ltd
SZSE:000623
22.5B CNY 9.6 8.8 -131.4 -131.4
US
Eli Lilly and Co
NYSE:LLY
986.9B USD 15.1 47.8 32.2 34.4
US
Johnson & Johnson
NYSE:JNJ
596.5B USD 6.3 22.3 15.4 19
CH
Roche Holding AG
SIX:ROG
293B CHF 4.8 31.2 13.1 15.3
CH
Novartis AG
SIX:NOVN
249.7B CHF 5.7 23 14.2 18.2
UK
AstraZeneca PLC
LSE:AZN
240.5B GBP 5.5 31.7 17.5 24.7
US
Merck & Co Inc
NYSE:MRK
305.9B USD 4.7 16.8 10.4 12.6
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.4 10.4 7.7 9
US
Pfizer Inc
NYSE:PFE
156.9B USD 2.5 20.2 7.7 10.3
US
Bristol-Myers Squibb Co
NYSE:BMY
125.6B USD 2.6 17.8 7.4 9.2
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Jilin Aodong Pharmaceutical Group Co Ltd
SZSE:000623
Average EV/EBITDA: 47.1
Negative Multiple: -131.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.2
22%
1.5
US
Johnson & Johnson
NYSE:JNJ
15.4
2%
7.7
CH
Roche Holding AG
SIX:ROG
13.1
5%
2.6
CH
Novartis AG
SIX:NOVN
14.2
5%
2.8
UK
AstraZeneca PLC
LSE:AZN
17.5
13%
1.3
US
Merck & Co Inc
NYSE:MRK
10.4
3%
3.5
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.7
2%
3.8
US
Pfizer Inc
NYSE:PFE
7.7
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.4
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Jilin Aodong Pharmaceutical Group Co Ltd
SZSE:000623
Average EV/EBIT: 101.8
Negative Multiple: -131.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.4
22%
1.6
US
Johnson & Johnson
NYSE:JNJ
19
7%
2.7
CH
Roche Holding AG
SIX:ROG
15.3
6%
2.6
CH
Novartis AG
SIX:NOVN
18.2
9%
2
UK
AstraZeneca PLC
LSE:AZN
24.7
21%
1.2
US
Merck & Co Inc
NYSE:MRK
12.6
6%
2.1
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9
3%
3
US
Pfizer Inc
NYSE:PFE
10.3
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
9.2
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett